Drug intelligence / Profile preview

Lycorine

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal, Oral, Intravenous, Subcutaneous

Overview

Lycorine is a natural pyrrolo[de]phenanthridine ring-type alkaloid extracted from the Amaryllidaceae plant family. It exhibits a wide range of physiological effects, including anti-cancer, anti-viral, anti-malarial, and anti-inflammatory. Although its exact mechanism of action is not fully understood, lycorine is considered a candidate for anti-inflammatory and anti-cancer treatments. It has been shown to inhibit cell proliferation and metastasis in various cancer types.

Other names: LycorinLicorineAmarylineBelamarineNarcissinNSC 401360NSC401360NSC-401360NSC 683873NSC683873NSC-683873

Targets

PDGFRA (Platelet-derived growth factor receptor alpha)TOP2A (DNA topoisomerase II)TOP1 (DNA Topoisomerase I)Acetylcholinesterase

Beyond the preview

Go deeper on Lycorine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lycorine.

Explore the full profile